The Mallinckrodt 2021

Advancing ECP Immunomodulation Investigator Award:
Refining THERAKOS ECP Immunomodulation™

Terms and Conditions

The following terms and conditions apply:

  • Submissions must demonstrate a significant focus on investigating the mechanisms behind THERAKOS ECP Immunomodulation™.

  • As part of the application process, applicants are required to provide a detailed outline of their plans for the grant funding according to the above-mentioned criteria. The provided template might serve as a guide for your application, but other formats are acceptable as well.

  • Applications without a detailed budget justification will not be accepted.

  • Project proposal must not only demonstrate a reasonable and detailed budget but also feasibility within a timeline of 12 months.

  • All submissions must be in English.

  • The winner must complete and sign the grant contract within an agreed timeline after selection. Failure to execute the contract in a timely manner may result in default of the award, in which case the runner-up would receive the award.

  • Projects are expected to be completed within one year following the distribution of funds.

  • Awardees are not nominated nor selected as an inducement or reward for purchasing, prescribing, using or recommending Mallinckrodt products.

  • Details of the award will also be declared in line with Transparency Reporting requirements.